Isotechnika Inc. (ISA-T) C$4.97
Preliminary Phase II-A Kidney Transplant Results Promising - Strong BUY
David Wingnean,
Eric Lun (Associate),
Stuart Wollach (Associate),
(TD Securities-Biotech/Health Care)
Isotechnika's Dr. Launa Aspeslet, VP QA and Regulatory Affairs, presented preliminary
results of its phase II-A kidney transplant study at the prestigious American Transplant
Congress in Washington, DC. In front of over a thousand transplant surgeons and
nephrologists, Dr. Aspeslet revealed that in the first six patients who finished a 12-week
course of ISAtx247, all patients exhibited stable serum creatinine (SCr) levels, indicating
that ISAtx247 is not kidney toxic. Dr. Aspeslet also revealed data that ISAtx247, using a
CN-inhibitor blood test, is 3X more potent than Neoral™ (cyclosporine). To reflect the
increased potency, ISA has modified the study protocol to dose ISAtx247 at 1/3 trough
levels of Neoral™ (previously 1/2). Dr. Aspeslet also mentioned some early results of the
phase II psoriasis study where there was also no evidence of kidney toxicity in the over 150
patients enrolled to date (4/5 subjects received ISAtx247). These are early, but very
promising results. |
